Skip to main content
OpenTrials
Completed

NCT Number: NCT07617103

Early vs. Late Tourniquet Release and Phlebotomy-Induced Hemolysis in the Emergency Department: TOURNI-ED

BACKGROUND:

Hemolysis is the most common preanalytical error in emergency department (ED) laboratories, affecting 12-26% of blood samples collected in the ED and leading to test cancellations, repeat venipuncture, delayed diagnoses, and increased healthcare costs. Venous stasis created by tourniquet application during phlebotomy is a recognized contributing factor to hemolysis. While clinical guidelines recommend releasing the tourniquet once blood flow is established, the optimal timing of tourniquet release in relation to tube filling sequence has not been systematically evaluated.

OBJECTIVE:

The primary objective of this trial is to determine whether early release of sphygmomanometer-applied venous stasis (released after the first tube fills) reduces hemolysis rates compared to late release (released after the last tube fills) during routine phlebotomy in ED patients triaged as green or yellow category.

DESIGN:

Single-center, parallel-group, superiority randomized controlled trial with 1:1 allocation ratio. The trial was prospectively registered prior to the enrollment of the first participant.

PARTICIPANTS:

Adult patients (≥18 years) presenting to the emergency department with triage category green (semi-urgent) or yellow (urgent), for whom blood collection is indicated as part of routine clinical care. At least two collection tubes had to be ordered, because the intervention is defined by the timing of cuff release relative to tube filling. Patients requiring blood collection from an intravenous catheter, those with known coagulation disorders, and those who decline to participate are excluded.

INTERVENTIONS:

Group A (Early Release): Sphygmomanometer inflated to 60 mmHg for venous stasis; tourniquet released as soon as blood flow into the first tube (sodium citrate, blue cap) is observed. All remaining tubes are collected after release.

Group B (Late Release): Sphygmomanometer inflated to 60 mmHg; tourniquet maintained throughout all tube filling and released only after the last collection tube completes filling. Tube collection order follows the CLSI H03-A6 standard for both groups.

PRIMARY OUTCOME:

Hemolysis rate, defined as the proportion of serum separator tube (SST/yellow cap) samples with a Hemolysis Index (HI) ≥ 1+ (corresponding to free hemoglobin ≥50 mg/dL), is assessed by the clinical chemistry laboratory analyzer. The outcome assessor (laboratory technician) is blinded to group assignment.

SECONDARY OUTCOMES:

(1) Distribution of ordinal hemolysis index categories (-, 1+, 2+, 3+, 4+, 5+) in SST samples; (2) Proportion of hemolyzed samples requiring repeat blood collection; (3) Duration of venous stasis (seconds), from sphygmomanometer inflation to deflation of the cuff; (4) Complication rate (hematoma or ecchymosis, local swelling, oozing at the puncture site, vasovagal reaction, nerve injury, arterial puncture, or more than two venipuncture attempts).

SAMPLE SIZE:

Assuming hemolysis rates of 12% with late release and 6% with early release, a 2-sided alpha of 0.05, 80% power, and the normal approximation for two proportions with pooled variance, 356 participants per group were required. Allowing approximately 10% attrition, the enrollment target was 396 per group (792 total), and this was reached.

RANDOMIZATION:

A restricted allocation sequence of 792 assignments in a 1:1 ratio, without stratification, was generated with Research Randomizer (randomizer.org) before the start of enrollment. The sequence as implemented is not consistent with any single fixed block size, so no block size is claimed. The complete sequence was fixed before the first participant was enrolled, was embedded in the electronic data collection application, and was not accessible to the enrolling nurse; a participant's allocation was released only after eligibility had been confirmed and the participant had been enrolled. The realized allocation was 396 participants per group.

STATISTICAL ANALYSIS:

Primary analysis: intention-to-treat, comparing hemolysis rates with the Pearson chi-square test with Yates continuity correction; the composite complication outcome was compared with the Pearson chi-square test without continuity correction. Secondary analyses: Mann-Whitney U test for the ordinal hemolysis index distribution and for continuous outcomes; logistic regression for the adjusted odds ratio. A Bonferroni-adjusted alpha of 0.0125 was applied across the four confirmatory secondary endpoints; exploratory analyses used alpha of 0.05. Per-protocol analysis was performed as a sensitivity analysis. Missing primary outcome data were addressed with four prespecified scenarios (complete case, best case, worst case, and a tipping-point analysis); the complete-case analysis is reported as primary.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Marmara University Pendik Training and Research Hospital

Pendik, Istanbul, 34899, Turkey (Türkiye)

About this study

BACKGROUND AND RATIONALE:

Hemolysis is recognized as the leading preanalytical source of error in clinical laboratories, with emergency department settings reporting particularly high rates (range: 12-26%) due to specimen collection under time pressure, use of small-bore intravenous catheters, and challenging venous access. Hemolyzed specimens affect measurements of potassium, lactate dehydrogenase, bilirubin, and other analytes, resulting in clinical misinterpretation, repeated laboratory requests, and procedural delays in a time-sensitive environment.

Venous stasis created by tourniquet application is a physiological perturbation that promotes erythrocyte deformation and lysis through hemoconcentration and shear stress. Clinical guidelines (Clinical and Laboratory Standards Institute, CLSI H03-A6; Turkish Biochemistry Society Phlebotomy Guidelines 2015) recommend that the tourniquet should be released as soon as blood flow is established, ideally within 60 seconds, and not later than the completion of the first collection tube. However, in routine emergency nursing practice, the tourniquet is frequently maintained throughout the entire multi-tube collection sequence to maintain venous distension and reduce the likelihood of failed collection attempts.

This pragmatic trial directly tests whether adherence to guideline-recommended early tourniquet release translates into a clinically meaningful reduction in hemolysis rates compared to the commonly observed late release practice, in a controlled setting using standardized sphygmomanometer-applied venous stasis at 60 mmHg.

INTERVENTION DELIVERY:

Both interventions use a standard aneroid sphygmomanometer (not a conventional tourniquet rubber strap) inflated to 60 mmHg to standardize venous stasis pressure across all participants. Applying stasis with a sphygmomanometer holds the pressure fixed and measurable, so that pressure does not vary between operators and the arms differ only in the timing of cuff release.

Tube collection order (identical for both groups, per CLSI H03-A6):

Sodium citrate (blue cap, 2.7 mL) - coagulation studies SST/gel separator (yellow cap, 5 mL) - serum biochemistry [PRIMARY OUTCOME TUBE] K2-EDTA (purple cap, 3 mL) - complete blood count

Additional tubes (for example a second biochemistry tube or a troponin tube) are drawn when ordered by the treating physician as part of routine clinical care; these additional tubes are not part of the study protocol. The total number of tubes per participant therefore ranges from 3 to 5.

Group A - Early Release Protocol: As soon as blood flow into the first tube (sodium citrate) is observed, the sphygmomanometer is deflated to 0 mmHg and removed. Subsequent tubes are collected without venous stasis.

Group B - Late Release Protocol: The sphygmomanometer remains inflated at 60 mmHg throughout the entire collection sequence. It is deflated and removed only after the last collection tube completes filling.

RANDOMIZATION AND ALLOCATION CONCEALMENT:

The allocation sequence was generated by the principal investigator before the start of enrollment, using Research Randomizer (randomizer.org), as a restricted list of 792 allocations in a 1:1 ratio without stratification. The block length is not reported, because the block structure of the generated list was not preserved in the sequence as implemented. The complete sequence was fixed before the first participant was enrolled; no sealed envelopes were used. The sequence was embedded in the electronic data collection application used at the bedside and was not accessible to the enrolling nurse; the application released a participant's allocation only after eligibility had been confirmed and the participant had been enrolled, so allocation concealment was maintained up to the point of enrollment. The realized allocation was 396 participants per group, and the largest cumulative imbalance between the groups at any point during enrollment was 4 participants.

DIFFICULTY ASSESSMENT - A-DIVA Scale: All participants are assessed for venous access difficulty using the modified A-DIVA (Adult Difficult Intravenous Access) Scale (van Loon et al., J Clin Med 2019;8(2):144) prior to blood collection. The modified A-DIVA scale assigns 0-1 points for each of five items: (1) history of difficult venous access, (2) no palpable vein, (3) no visible vein, (4) vein diameter <3 mm, (5) difficult venous access anticipated by the operator. Total score ≥2 is classified as high-difficulty. The A-DIVA score is recorded as a covariate in statistical analysis.

HEMOLYSIS ASSESSMENT:

The Hemolysis Index (HI) is measured on all SST/yellow cap tube specimens by the clinical chemistry analyzer (DxC series; Beckman Coulter, Brea, CA), which reports each serum specimen either as negative for hemolysis or as an integer hemolysis index. The laboratory maps these values onto a six-category ordinal scale corresponding to free hemoglobin concentrations: (-) <50 mg/dL, (1+) 50-99 mg/dL, (2+) 100-199 mg/dL, (3+) 200-299 mg/dL, (4+) 300-500 mg/dL, (5+) >500 mg/dL. Laboratory technicians performing HI analysis are blinded to group assignment throughout the study.

BLINDING:

Participants and the nurse performing venipuncture could not be blinded: the consent process described both release timings, and the timing of cuff release is visible at the bedside. The outcome assessor (the laboratory technician recording the hemolysis index) was blinded to allocation, as was the analyst until the analysis plan, which was fixed before enrollment began, was finalized. Each tube carried its own laboratory information system barcode; the serum separator gel tube was identified by that barcode alone, the allocated group appeared neither on the request nor on the tube, and the hemolysis index recorded against that barcode was the value transcribed into the data set.

PATIENT AND PUBLIC INVOLVEMENT (CONSORT 2025 Item 8):

Patients and the public were not formally involved in the design of this trial due to the pragmatic, low-risk, procedure-modification nature of the study. Findings will be disseminated through open-access publication and presented to nursing and laboratory staff at the participating institution.

DATA SHARING (CONSORT 2025 Item 4):

De-identified individual participant data and the data dictionary will be made available to qualified researchers upon reasonable written request to the principal investigator, following publication of the primary manuscript and approval by the institutional ethics committee, in accordance with applicable data protection regulations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Presenting to the emergency department and triaged as green (semi-urgent) or yellow (urgent) category according to the Emergency Severity Index (ESI) or equivalent institutional triage system
  • Blood collection (venipuncture) indicated as part of routine clinical care by the attending emergency physician
  • Ability to provide written informed consent
  • Accessible peripheral vein suitable for standard venipuncture, most often in the antecubital fossa but at the operator's discretion an alternative peripheral site such as the dorsum of the hand (not requiring intravenous catheter placement for blood collection)

Exclusion criteria

  • Blood collection performed via an existing intravenous catheter or central venous access device
  • Critical illness or hemodynamic instability, including triage category red (resuscitation) at the time of blood collection
  • Anticoagulant or thrombolytic therapy, or any condition in which collection of a coagulation tube was contraindicated, including a known or suspected coagulation disorder (e.g., hemophilia, thrombocytopenia with platelet count <50,000/uL)
  • Known hemolytic disease, a history of active hemolysis, or another hematological condition associated with baseline elevated hemolysis
  • Red blood cell transfusion within the preceding 24 hours
  • Pregnancy of any gestational age
  • Absence of a peripheral vein suitable for standard venipuncture
  • Local pathology preventing collection from the antecubital fossa: infection, hematoma, burn, active upper extremity injury, lymphedema, an arteriovenous fistula, or the side of a previous mastectomy
  • Only a single collection tube ordered (the intervention requires at least two tubes, because it is defined by the timing of cuff release relative to tube filling)
  • Inability to give informed consent, or declining to participate
  • Previously enrolled in this study (re-enrollment not permitted)

Treatment and study plan

Sphygmomanometer-Applied Venous Stasis with Varied Release Timing During Phlebotomy

Procedure

A standard aneroid sphygmomanometer is used in place of a conventional tourniquet rubber strap to apply venous stasis at a standardized pressure of 60 mmHg prior to venipuncture. Blood is collected in the following order, per CLSI H03-A6: (1) sodium citrate tube (blue cap, 2.7 mL), (2) serum separator tube/SST (yellow cap, 5 mL), (3) K2-EDTA tube (purple cap, 3 mL). Additional tubes are drawn when ordered by the treating physician as part of routine clinical care, so the total number of tubes per participant ranges from 3 to 5. The intervention variable is the timing of sphygmomanometer release: at the first sign of blood flow into the first tube (Group A, early release) versus after the last tube has filled (Group B, late release).

Other names: Tourniquet Release Timing; Venous Stasis Duration; Phlebotomy Technique Modification

Primary outcomes

  1. Hemolysis Rate (Proportion of Hemolyzed Serum Separator Tube Specimens)

    Time frame: Measured at the time of laboratory analysis, within 2 hours of blood collection

    The proportion of serum separator tube (SST/yellow cap) specimens with a Hemolysis Index (HI) of ≥1+ (corresponding to free hemoglobin concentration ≥50 mg/dL), as measured by the clinical chemistry laboratory analyzer. The HI is reported on a six-category ordinal scale: (-) <50 mg/dL; (1+) 50-99 mg/dL; (2+) 100-199 mg/dL; (3+) 200-299 mg/dL; (4+) 300-500 mg/dL; (5+) >500 mg/dL. A specimen is classified as hemolyzed if HI ≥1+.

Secondary outcomes

  1. Ordinal Distribution of Hemolysis Index Categories

    Time frame: Measured at the time of laboratory analysis, within 2 hours of blood collection

    Distribution of specimens across six Hemolysis Index categories (-, 1+, 2+, 3+, 4+, 5+) in SST/yellow cap tubes, analyzed as an ordinal variable to characterize severity of hemolysis beyond the binary primary outcome.

  2. Proportion of Specimens Requiring Repeat Blood Collection Due to Hemolysis

    Time frame: Within the same emergency department visit (up to 24 hours post-collection)

    The proportion of participants whose SST/yellow cap specimen was reported as unsuitable for analysis due to hemolysis and for whom a repeat blood collection was clinically requested by the attending physician, resulting in a second venipuncture within the same emergency department visit.

  3. Duration of Venous Stasis

    Time frame: Measured during the blood collection procedure

    Time in seconds of applied venous stasis, measured with a stopwatch from inflation of the sphygmomanometer cuff to 60 mm Hg until deflation of the cuff. In the early-release group the cuff is deflated as soon as blood flow into the first collection tube is observed; in the late-release group the cuff is deflated after the last collection tube has filled.

  4. Procedural Complication Rate

    Time frame: During the blood collection procedure and up to 30 minutes post-procedure

    The proportion of participants experiencing any of the following procedure-related complications, or more than two venipuncture attempts: hematoma or ecchymosis at the puncture site, local swelling, oozing at the puncture site, vasovagal reaction (syncope or pre-syncope), nerve injury (persistent paresthesia >30 minutes), or accidental arterial puncture. Complications were assessed systematically for every participant by the nurse performing the collection, during the procedure and for up to 30 minutes afterwards.

Sponsors and collaborators

Lead sponsor

Marmara University Pendik Training and Research Hospital

Other

Registry information

Official study title

Early Versus Late Release of Sphygmomanometer-Applied Venous Stasis and Phlebotomy-Induced Hemolysis in the Emergency Department: A Parallel-Group Randomized Controlled Trial

Acronym: TOURNI-ED

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 1, 2026
Registry last updated
Aug 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.